Cancer de l'ovaire (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cancer de l'ovaire" in French language version.

refsWebsite

Global rank French rank

20nih.gov

4^th place

12^th place

6thelancet.com

2,393^rd place

506^th place

6ascopubs.org

low place

7,741^st place

4nejm.org

2,374^th place

298^th place

3wikipedia.org

low place

3oxfordjournals.org

1,389^th place

508^th place

3wiley.com

222^nd place

129^th place

2sante.fr

8,603^rd place

517^th place

2jamanetwork.com

2,650^th place

689^th place

1doi.org

2^nd place

3^rd place

1lww.com

2,769^th place

931^st place

1fnclcc.fr

low place

5,283^rd place

ascopubs.org

jco.ascopubs.org

(en) Schumer ST, Cannistra SA, « Granulosa cell tumor of the ovary » J Clin Oncol. 2003;21:1180-1189. PMID 12637488
(en) Bristow RE, Tomacruz RS, Armstrong DK. et al. « Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis » J Clin Oncol. 2002;20:1248-1259. PMID 11870167
(en) Winter WE 3rd, Maxwell GL, Tian C. et al. « Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study » J Clin Oncol. 2008;26(1):83-9. PMID 18025437
(en) Markman M, Walker JL, « Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment » J Clin Oncol. 2006;24:988-994.
(en) Pfisterer J, Plante M, Vergote I et al. « Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG » J Clin Oncol. 2006;24:4699-4707.
(en) Burger RA, Sill MW, Monk BJ et al. « Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study » J Clin Oncol. 2007;25: 5165-5171.

doi.org

« Significantly elevated radiation-related risk was seen for cancers of organs proximal to the radiation source or fields (bladder, rectum and ovary), as well as for non-chronic lymphocytic leukemia » in Ritsu Sakata, Ruth A. Kleinerman, Kiyohiko Mabuchi, Marilyn Stovall, Susan A. Smith, Rita Weathers, Jean Wactawski-Wende, Diane L. Cookfair, John D. Boice, Jr., and Peter D. Inskip (2012) Cancer Mortality Following Radiotherapy for Benign Gynecologic Disorders. Radiation Research: October 2012, Vol. 178, No. 4, pp. 266-279. https://doi.org/10.1667/RR2845.1

fnclcc.fr

RECOMMANDATIONS POUR LA PRATIQUE CLINIQUE Standards, Options : Recommandations 2007 pour la prise en charge des patientes atteintes de tumeurs épithéliales malignes de l’ovaire « Traitement chirurgical »

jamanetwork.com

jama.jamanetwork.com

(en) Goff B, Mandel L, Melancon CH, Muntz HG, « Frequency of symptoms of ovarian cancer in women presenting to primary care clinics » JAMA. 2004;291:2705-12. PMID 15187051

jamanetwork.com

Henderson JT, Webber EM, Sawaya GF, Screening for ovarian cancer: US Preventive Services Task Force recommendation statement; JAMA, 2018;319:595-606

lww.com

journals.lww.com

Zapardiel I, Gorostidi M, Ravaggi A, Allende MT, Silveira M, Macuks R, Utility of human epididymis protein 4 serum marker for the detection of adnexal malignancy: a multicentric prospective study, Eur J Cancer Prev, 2017;26:346-350

nejm.org

content.nejm.org

(en) Armstrong DK, Bundy B, Wenzel L et al. « Intraperitoneal cisplatin and paclitaxel in ovarian cancer » N Engl J Med. 2006;354:34-43.
(en) van der Burg ME, van Lent M, Buyse M. et al. « The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer » N Engl J Med. 1995;332:629-634.
(en) Rose PG, Nerenstone S, Brady MF. et al. « Secondary surgical cytoreduction for advanced ovarian carcinoma » N Engl J Med. 2004;351:2489-2497.
(en) Rebbeck TR, Lynch HT, Neuhausen SL et al. « Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations » N Engl J Med. 2002;346:1616-1622

nih.gov

ncbi.nlm.nih.gov

(en) Weyer PJ, JR Cerhan, BC Kross, GR Hallberg, J Kantamneni, G Breuer, MP Jopnes, W Zheng et CF Lynch « Municipal drinking water nitrate level and cancer risk in older women: The Iowa Women's Health Study » Epidemiology 2001;12:327–338. PMID 11338313
(en) Hughes E, Brown J, Collins J, Vanderkerckhove P. « Clomiphene citrate for unexplained subfertility in women » Cochrane Database Syst Rev. 2000;(1):CD000057. PMID 10908459
(en) Jensen A, Sharif H, Frederiksen K, Kjaer SK, « Use of fertility drugs and subsequent risk for ovarian cancer: Danish population based cohort study » BMJ 2009;338:b249. PMID 19196744
(en) Fathalla MF, « Incessant ovulation—a factor in ovarian neoplasia? » Lancet. 1971;298:163. PMID 4104488
(en) Cramer DW, Welch WR, « Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis » J Natl Cancer Inst. 1983;71:717-721. PMID 6578367
(en) Pearce CL, Templeman C, Rossing MA. et al. « Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies » Lancet Oncol. 2012;13:385–394. PMID 22361336
(en) Goff B, Mandel L, Melancon CH, Muntz HG, « Frequency of symptoms of ovarian cancer in women presenting to primary care clinics » JAMA. 2004;291:2705-12. PMID 15187051
(en) Timmerman D, Valentin L, Bourne TH, Collins WP, Verrelst H, Vergote I, International Ovarian Tumor Analysis (IOTA) Group, « Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group » Ultrasound Obstet Gynecol. 2000;16:500-505. PMID 11169340
(en) Schumer ST, Cannistra SA, « Granulosa cell tumor of the ovary » J Clin Oncol. 2003;21:1180-1189. PMID 12637488
(en) du Bois A, Quinn M, Thigpen T. et al. « 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) » Ann Oncol. 2005;16(suppl 8):viii7-viii12 PMID 16239238
(en) Bristow RE, Tomacruz RS, Armstrong DK. et al. « Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis » J Clin Oncol. 2002;20:1248-1259. PMID 11870167
(en) Young RC, Decker DG, Wharton JT. et al. « Staging laparotomy in early ovarian cancer » JAMA. 1983;250:3072-3076. PMID 6358558
(en) Winter WE 3rd, Maxwell GL, Tian C. et al. « Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study » J Clin Oncol. 2008;26(1):83-9. PMID 18025437
(en) Aabo K, Adams M, Adnitt P, Alberts DS, Yeap BY et al.; Advanced Ovarian Cancer Trialists' Group, « Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group », Br J Cancer, vol. 78, n^o 11,‎ 1998, p. 1479-87. (PMID 9836481, PMCID PMC2063202, lire en ligne [html]) modifier
(en) Muggia FM, Braly PS, Brady MF, Sutton G, Small JM et al., « Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study », J Clin Oncol, vol. 18, n^o 1,‎ 2000, p. 106-15. (PMID 10623700) modifier
(en) International Collaborative Ovarian Neoplasm Group, « Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial », Lancet, vol. 360, n^o 9332,‎ 2002, p. 505-15. [Erratum in Lancet. 2003 Feb 22;361(9358):706.] (PMID 12241653) modifier
(en) Dedrick RL, Myers CE, Bungay PM et al. « Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer » Cancer Treat Rep. 1978;62:1-9.
Young RC, Walton LA, Ellenberg SS et als. Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials, N Engl J Med, 1990;322:1021-1027
(en) International Collaborative Ovarian Neoplasm (ICON1), European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant Chemotherapy in Ovarian Neoplasm (EORTC-ACTION), « International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy in Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma » J Natl Cancer Inst. 2003;95:105-112. PMID 12529343
(en) Burke W, Daly M, Garber J et al. « Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium » JAMA. 1997;277:997-1003

oxfordjournals.org

annonc.oxfordjournals.org

Recommandations 2007 de l'ESMO
(en) du Bois A, Quinn M, Thigpen T. et al. « 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) » Ann Oncol. 2005;16(suppl 8):viii7-viii12 PMID 16239238

jnci.oxfordjournals.org

(en) Risch HA, McLaughlin JR, Cole DE. et al. « Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada » J Natl Cancer Inst. 2006;98:1694-1706.

sante.fr

invs.sante.fr

thelancet.com

(en) Hennessy BT, Coleman RL, Markman M, « Ovarian cancer » Lancet. 2009;374:1371-1382.
(en) Collaborative Group on Epidemiological Studies of Ovarian Cancer, « Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23257 women with ovarian cancer and 87303 controls » Lancet. 2008;371:303-314.
(en) Beral V, Million Women Study Collaborators, « Ovarian cancer and hormone replacement therapy in the Million Women Study » Lancet 2007;369:1703-1710
(en) Fathalla MF, « Incessant ovulation—a factor in ovarian neoplasia? » Lancet. 1971;298:163. PMID 4104488
(en) Pearce CL, Templeman C, Rossing MA. et al. « Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies » Lancet Oncol. 2012;13:385–394. PMID 22361336
(en) The ICON and AGO Collaborators, « Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial » Lancet. 2003;361:2099-2106

wikipedia.org

fr.wikipedia.org

(en) Aabo K, Adams M, Adnitt P, Alberts DS, Yeap BY et al.; Advanced Ovarian Cancer Trialists' Group, « Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group », Br J Cancer, vol. 78, n^o 11,‎ 1998, p. 1479-87. (PMID 9836481, PMCID PMC2063202, lire en ligne [html]) modifier
(en) Muggia FM, Braly PS, Brady MF, Sutton G, Small JM et al., « Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study », J Clin Oncol, vol. 18, n^o 1,‎ 2000, p. 106-15. (PMID 10623700) modifier
(en) International Collaborative Ovarian Neoplasm Group, « Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial », Lancet, vol. 360, n^o 9332,‎ 2002, p. 505-15. [Erratum in Lancet. 2003 Feb 22;361(9358):706.] (PMID 12241653) modifier

wiley.com

Cancer de l'ovaire (French Wikipedia)

ascopubs.org

jco.ascopubs.org

doi.org

fnclcc.fr

jamanetwork.com

jama.jamanetwork.com

jamanetwork.com

lww.com

journals.lww.com

nejm.org

content.nejm.org

nih.gov

ncbi.nlm.nih.gov

oxfordjournals.org

annonc.oxfordjournals.org

jnci.oxfordjournals.org

sante.fr

invs.sante.fr

thelancet.com

wikipedia.org

fr.wikipedia.org

wiley.com

mrw.interscience.wiley.com

www3.interscience.wiley.com

onlinelibrary.wiley.com